Est. 2001·3,000+ placements · six offices · four regions
M&A Activitycurated sourcedetected 2026-07-14 · confidence 70%

Last updated

Teva Pharmaceuticals: M&A Activity

Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.

Source: STAT News (Pharmalot)

Who
Teva Pharmaceuticals · Biotech & Pharma · Australia & New Zealand
What happened
Active litigation against Eli Lilly with appeals court victory reviving lawsuit. Teva won the ability to challenge Lilly's FDA exclusivity extension that delayed its generic Forteo launch. Large-scale legal battle ongoing with significant business implications.
When
2026-07-14

Market context: MitchelLake's Talent Market Index sits at 95.4 (Cool), down 5.3 on the prior month; Oceania hiring signal is running rising (+8.2pts).

Teva Pharmaceuticals: 1 signal in the last 90 days — in line with the Biotech & Pharma median of 1 across 31 tracked companies; 0.1% of MitchelLake's Oceania signal flow; 4 tracked across 50 days.

MitchelLake in this thematic

Also at Teva Pharmaceuticals →

More signals across Biotech & Pharma

M&A Activity · Oceania

UCB →

UCB completed $2B acquisition of Candid Therapeutics, acquiring two clinical-stage T cell engagers for autoimmune disorders

Partnership · Oceania

NeuroScientific Biopharmaceuticals →

NeuroScientific Biopharmaceuticals has engaged Southern Star Research to conduct a phase two clinical trial of its StemSmart Crohn's disease therapy in Australia and the US.

Partnership · Oceania

AusBiotech →

AusBiotech announced a strategic partnership with Tenmile venture capital firm to strengthen ecosystem connections and help Australian health startups access both domestic and international capital. The partnership extends prior collaboration on the Early Stage Innovation Forum and creates additional opportunities for startups and scale-ups.

M&A Activity · Americas

Repligen Corporation →

Repligen completed acquisition of BioLife Solutions for $11.25/share cash plus stock consideration. Transaction consolidates cell therapy bioprocessing capabilities and expands Repligen's product portfolio in high-growth cell and gene therapy market.

M&A Activity · Americas

Amgen →

Amgen is terminating its partnership with TScan Therapeutics, a T cell therapy company based in Waltham, MA.

M&A Activity · Americas

BioMarin Pharmaceutical Inc. →

BioMarin agreed to acquire Alesta Therapeutics for up to $490 million ($275M upfront + $215M in milestones) to add ALE1, a clinical-stage oral therapy for hypophosphatasia (rare genetic bone disease), to its rare disease pipeline.

Where this lands in our work

Weekly briefing

Track companies like Teva Pharmaceuticals — with our analysis

Anyone can set an alert for one company. We send a weekly read on the whole peer set — who's moving, and what it means for leadership. Pick what to follow:

Intelligence powered by Autonodal ↗

Nearby in the record